Doximity Analyst Ratings
BenzingaApr 25 08:45 ET
JPMorgan Upgrades Doximity to Neutral Rating From Underweight, Price Target Is $25
MT NewswiresApr 25 07:08 ET
Doximity Analyst Ratings
BenzingaApr 23 12:23 ET
Doximity Analyst Ratings
BenzingaApr 2 07:02 ET
Doximity Analyst Ratings
BenzingaMar 15 10:07 ET
Doximity Analyst Ratings
BenzingaFeb 26 08:37 ET
Truist Securities Maintains Hold on Doximity, Raises Price Target to $29-Report Released on 8th February 2024
BenzingaFeb 9 16:46 ET
Doximity Analyst Ratings
BenzingaFeb 9 16:45 ET
Doximity Analyst Ratings
BenzingaFeb 9 09:24 ET
Doximity Growth Prospects and Buy Rating Endorsed Amid Economic Caution
TipRanksFeb 9 08:17 ET
Analysts Conflicted on These Healthcare Names: Doximity (DOCS) and AbbVie (ABBV)
TipRanksFeb 9 07:10 ET
Doximity (DOCS) Maintains Hold Rating Amid Mixed Growth Signals and Potential Catalysts
TipRanksFeb 9 06:48 ET
Doximity Sell Rating: Concerns Over Q4 Guidance and Market Share Outlook
TipRanksFeb 9 06:47 ET
Analysts' Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Edwards Lifesciences (EW) and Doximity (DOCS)
TipRanksFeb 7 06:40 ET
Analysts Conflicted on These Healthcare Names: Intuitive Surgical (ISRG), Madrigal Pharmaceuticals (MDGL) and Doximity (DOCS)
TipRanksJan 24 07:41 ET
Doximity Analyst Ratings
BenzingaJan 23 16:17 ET
Doximity's Hold Rating Maintained Amidst Market Optimism and Growth Challenges
TipRanksJan 23 06:07 ET
Truist Financial Keeps Their Hold Rating on Doximity (DOCS)
TipRanksJan 7 21:26 ET
Doximity Raised at BofA, GoodRx Holdings Double-downgraded
InvestingJan 2 12:06 ET
Doximity (DOCS) Gets a Hold From BTIG
TipRanksJan 2 09:22 ET
No Data
No Data